Zobrazeno 1 - 10
of 86
pro vyhledávání: ''
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Encarnação Teixeira, Sousa Ac, Martins J, Janeiro A, Malveiro S, M. Felizardo, Oliveira Ar, Nogueira F, Maria Carmo-Fonseca, Silveira C
Publikováno v:
Lung Cancer. 139:35-40
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKI
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl
Autor:
Jessica A. Hellyer, Sukhmani K. Padda, Joel W. Neal, Millie Das, Heather A. Wakelee, Henning Stehr, Maximilian Diehn, Kavitha Ramchandran
Publikováno v:
Lung Cancer. 134:42-45
Objectives For patients with Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), frontline EGFR-tyrosine kinase inhibitor (TKI) therapy compared to chemotherapy improves outcomes. However, resistance to these agents un
Autor:
Nicole J. Caixeiro, Wei Chua, P. de Souza, Joseph W. Po, David A. Lynch, Victoria J Bray, Alison W S Luk, Therese M. Becker, Yafeng Ma, Tara L. Roberts, Pei N Ding
Publikováno v:
Lung Cancer. 134:187-193
To determine the predictive and prognostic roles of three blood-based biomarkers: circulating tumour DNA (ctDNA), circulating tumour cells (CTC) and carcinoembryonic antigen (CEA), in patients with advanced epidermal growth factor receptor-mutated (E
Publikováno v:
Lung Cancer. 133:103-109
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line standard treatment for advanced lung adenocarcinoma with mutant EGFR. Nevertheless, few studies have demonstrated the efficacy of first- and s
Autor:
Katsuyuki Hotta, Kadoaki Ohashi, Katsuyuki Kiura, Toshio Kubo, Yoshinobu Maeda, Kammei Rai, Hisaaki Tanaka, Masahiro Tabata, Eiki Ichihara, Kiichiro Ninomiya
Publikováno v:
Lung Cancer. 132:54-58
Background Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). However, there is no established strategy for treatment fol
Autor:
Hiroaki Akamatsu, Daichi Fujimoto, Kazuhiko Nakagawa, Yasuhiro Koh, Akihiro Bessho, Nobuyuki Yamamoto, Satoshi Morita, Koichi Azuma, Isamu Okamoto
Publikováno v:
Lung Cancer. 131:128-133
Liquid biopsy has been approved as an optional method to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). However, the clinical significance of its utility for monitoring the disease remains elusive. WJO
Autor:
Yi-Hsuan Lee, Te-Jen Su, Kang-Yi Su, Mong-Wei Lin, Chia-Ching Chang, Jin-Shing Chen, Min-Shu Hsieh, Sung-Liang Yu, Jing-Wei Lin
Publikováno v:
Lung Cancer. 125:282-290
Objective Histologic transformation from adenocarcinoma to small cell lung cancer (SCLC) is one of the mechanisms of acquired resistance after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. Furthermore, de novo com